NCT05433935Recruiting
Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
A Prospective, Open Large Cohort Study of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
Source: ClinicalTrials.gov · Last updated 27 Jan 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a prospective, open large cohort study to explore biomarkers for detecting early carcinogenesis of IPMN.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 5000 (estimated)
- First submitted
- 22 Jun 2022
- Start date
- 1 Jul 2022
- Primary completion date
- 30 Jun 2032
- Lead sponsor
- Zhejiang University
- Diseases
- Pancreatic cancer, Childhood cancers
- NCT number
- NCT05433935
What you commit to
- Study type: Observational
- Planned participants: 5000
- From 1 Jul 2022 to the primary completion date, 30 Jun 2032
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- with mental disorders which can affect cognition and cooperation;
- with serious blood diseases or taking drugs that can affect peripheral blood
Who the study is looking for
- clinically diagnosed as IPMN;
- without other malignant tumor;
- agree to sign informed consent.
Age in the registry: 0 years to 90 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The first Affiliated Hospital, School of Medicine, Zhejiang University. Coordinator of this site? Confirm its status | Hangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.